U.S. Markets open in 9 hrs 4 mins
  • S&P Futures

    3,662.00
    -5.25 (-0.14%)
     
  • Dow Futures

    29,821.00
    -47.00 (-0.16%)
     
  • Nasdaq Futures

    12,466.00
    +11.75 (+0.09%)
     
  • Russell 2000 Futures

    1,831.90
    -5.60 (-0.30%)
     
  • Crude Oil

    45.19
    -0.09 (-0.20%)
     
  • Gold

    1,837.50
    +7.30 (+0.40%)
     
  • Silver

    24.10
    +0.08 (+0.33%)
     
  • EUR/USD

    1.2123
    +0.0007 (+0.0606%)
     
  • 10-Yr Bond

    0.9480
    +0.0140 (+1.50%)
     
  • Vix

    21.17
    +0.40 (+1.93%)
     
  • GBP/USD

    1.3390
    +0.0014 (+0.1058%)
     
  • USD/JPY

    104.4460
    +0.0220 (+0.0211%)
     
  • BTC-USD

    19,100.17
    +18.82 (+0.10%)
     
  • CMC Crypto 200

    374.82
    +9.91 (+2.71%)
     
  • FTSE 100

    6,463.39
    +78.66 (+1.23%)
     
  • Nikkei 225

    26,761.48
    -39.50 (-0.15%)
     

Otonomy: Q3 Earnings Insights

Benzinga Insights
·1 min read

Shares of Otonomy (NASDAQ:OTIC) were flat after the company reported Q3 results.

Quarterly Results

Earnings per share were up 33.33% over the past year to ($0.22), which beat the estimate of ($0.24).

Revenue of $50,000 decreased by 60.00% year over year, which were in line with the estimate of $50,000.

Guidance

Otonomy hasn't issued any earnings guidance for the time being.

Otonomy hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: Nov 04, 2020

View more earnings on OTIC

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/kp93rdg9

Technicals

52-week high: $4.89

Company's 52-week low was at $1.53

Price action over last quarter: down 2.68%

Company Overview

Otonomy Inc is a biopharmaceutical company, focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. The company also develops OTO-104, a sustained-exposure formulation of the steroid dexamethasone for the treatment of Meniere's disease and other inner ear conditions; and OTO-311, a sustained-exposure formulation for the treatment of tinnitus. All the business activity is primarily operates through the region of United States.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.